{"id":330374,"date":"2021-01-08T16:20:21","date_gmt":"2021-01-08T15:20:21","guid":{"rendered":"https:\/\/medizinonline.com\/state-of-the-art-in-ibd-treatment\/"},"modified":"2021-01-08T16:20:21","modified_gmt":"2021-01-08T15:20:21","slug":"state-of-the-art-in-ibd-treatment","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/state-of-the-art-in-ibd-treatment\/","title":{"rendered":"State of the art in IBD treatment"},"content":{"rendered":"

The classic symptoms of inflammatory bowel disease (IBD) range from mild abdominal pain to colicky symptoms and persistent diarrhea. Phases of low disease activity may be followed by severe episodes. The etiopathogenesis is thought to be multifactorial, with a combination of endogenous and exogenous factors involved in immune dysregulation, resulting in chronic inflammation in the gut.<\/p>\n

<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

\"\"Patients often require lifelong treatment to control symptoms and improve quality of life. The therapeutic landscape has changed rapidly in recent years, and several new, highly effective substances from the biologics and small molecule drug groups have come onto the market, particularly for moderate and severe forms of the disease. Read the first article in the series “IBD matters” and get a comprehensive overview of the Modern “State-of-the-Art” Pharmacotherapy in Inflammatory Bowel Disease.<\/p>\n